We also found a pharmacogenetic effect of the MMP9 R668Q polymorphism to increased stroke risk, although this association may be due to the small number of events (17 in the chlorthalidone group, 3 in the amlodipine group). This evidence concerns the gene MMP9 and stroke disorder.